Brain freeze.

The landmark IMpower133 trial demonstrated an improvement in overall survival with the addition of atezolizumab to the long-time standard of carboplatin + etoposide for extensive-stage small cell lung cancer (ES-SCLC). Here (LBA 3) we take a deeper look at patterns of recurrence with this now-standard triple-therapy combo. Most interesting was that median time to intracranial progression, defined as getting brain irradiation or new brain mets, was nearly doubled in patients receiving atezo (20 months) versus not (11 months). Otherwise, initial sites of disease accounted for well over half of recurrences in both arms. TBL: While this supports the utility of consolidative radiation, the addition of atezo may further obviate the need for prophylactic cranial irradiation for ES-SCLC. | Higgins, ASTRO 2020